|
1
|
Orimo H, Nakamura T, Fukunaga M, et al:
Effects of alendronate plus alfacalcidol in osteoporosis patients
with a high risk of fracture: The Japanese Osteoporosis
Intervention Trial (JOINT)-02. Curr Med Res Opin. 27:1273–1284.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ushiroyama T, Ikeda A, Sakai M,
Higashiyama T and Ueki M: Effects of the combined use of calcitonin
and 1 alpha-hydroxycholecalciferol on vertebral bone loss and bone
turnover in women with postmenopausal osteopenia and osteoporosis:
A prospective study of long-term and continuous administration with
low dose calcitonin. Maturitas. 40:229–238. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kobayashi M, Hara K and Akiyama Y: Effects
of vitamin K2 (menatetrenone) and alendronate on bone mineral
density and bone strength in rats fed a low-magnesium diet. Bone.
35:1136–1143. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Price PA: Vitamin K-dependent formation of
bone Gla protein (osteocalcin) and its function. Vitam Horm.
42:65–108. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tabb MM, Sun A, Zhou C, et al: Vitamin K2
regulation of bone homeostasis is mediated by the steroid and
xenobiotic receptor SXR. J Biol Chem. 278:43919–43927. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Igarashi M, Yogiashi Y, Mihara M, Takada
I, Kitagawa H and Kato S: Vitamin K induces osteoblast
differentiation through pregnane X receptor-mediated
transcriptional control of the Msx2 gene. Mol Cell Biol.
27:7947–7954. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Akiyama Y, Hara K, Kobayashi M, Tomiuga T
and Nakamura T: Inhibitory effect of vitamin K2 (menatetrenone) on
bone resorption in ovariectomized rats: A histomorphometric and
dual energy X-ray absorptiometric study. Jpn J Pharmacol. 80:67–74.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hara K, Akiyama Y, Nakamura T, Murota S
and Morita I: The inhibitory effect of vitamin K2 (menatetrenone)
on bone resorption may be related to its side chain. Bone.
16:179–184. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shiraki M, Shiraki Y, Aoki C and Miura M:
Vitamin K2 (menatetrenone) effectively prevents fractures and
sustains lumbar bone mineral density in osteoporosis. J Bone Miner
Res. 15:515–521. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Inoue T, Fujita T, Kishimoto H, Makino T,
Nakamura T, Nakamura T, Sato T and Yamazaki K: Randomized
controlled study on the prevention of osteoporotic fractures (OF
study): A phase IV clinical study of 15-mg menatetrenone capsules.
J Bone Miner Metab. 27:66–75. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Iwamoto J: Vitamin K2 therapy
for postmenopausal osteoporosis. Nutrients. 6:1971–1980. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Feskanich D, Weber P, Willett WC, Rockett
H, Booth SL and Colditz GA: Vitamin K intake and hip fractures in
women: A prospective study. Am J Clin Nutr. 69:74–79.
1999.PubMed/NCBI
|
|
13
|
Tam CS, Heersche JN, Murray TM and Parsons
JA: Parathyroid hormone stimulates the bone apposition rate
independently of its resorptive action: Differential effects of
intermittent and continuous administration. Endocrinology.
110:506–512. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rubin MR, Cosman F, Lindsay R and
Bilezikian JP: The anabolic effects of parathyroid hormone.
Osteoporos Int. 13:267–277. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rosen CJ: The role of parathyroid hormone
in the management of osteoporosis. Horm Res. 64 (Suppl 2):81–85.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kishi T, Hagino H, Kishimoto H and
Nagashima H: Bone responses at various skeletal sites to human
parathyroid hormone in ovariectomized rats: Effects of long-term
administration, withdrawal, and readministration. Bone. 22:515–522.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Okimoto N, Tsurukami H, Okazaki Y, Nishida
S, Sakai A, Ohnishi H, Hori M, Yasukawa K and Nakamura T: Effects
of a weekly injection of human parathyroid hormone (1–34) and
withdrawal on bone mass, strength, and turnover in mature
ovariectomized rats. Bone. 22:523–531. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Neer RM, Arnaud CD, Zanchetta JR, et al:
Effect of parathyroid hormone (1–34) on fractures and bone mineral
density in postmenopausal women with osteoporosis. N Engl J Med.
344:1434–1441. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miyauchi A, Matsumoto T, Sugimoto T,
Tsujimoto M, Warner MR and Nakamura T: Effects of teriparatide on
bone mineral density and bone turnover markers in Japanese subjects
with osteoporosis at high risk of fracture in a 24-month clinical
study: 12-month, randomized, placebo-controlled, double-blind and
12-month open-label phases. Bone. 47:493–502. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dempster DW, Cosman F, Kurland ES, et al:
Effects of daily treatment with parathyroid hormone on bone
microarchitecture and turnover in patients with osteoporosis: A
paired biopsy study. J Bone Miner Res. 16:1846–1853. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shimizu T, Takahata M, Kameda Y, Hamano H,
Ito T, Kimura-Suda H, Todoh M, Tadano S and Iwasaki N: Vitamin
K-dependent carboxylation of osteocalcin affects the efficacy of
teriparatide (PTH(1–34)) for skeletal repair. Bone. 64:95–101.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Turner RT, Vandersteenhoven JJ and Bell
NH: The effects of ovariectomy and 17 beta-estradiol on cortical
bone histomorphometry in growing rats. J Bone Miner Res. 2:115–122.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kalu DN: The ovariectomized rat model of
postmenopausal bone loss. Bone Miner. 15:175–191. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Koshihara Y and Hoshi K: Vitamin K2
enhances osteocalcin accumulation in the extracellular matrix of
human osteoblasts in vitro. J Bone Miner Res. 12:431–438. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Iwasaki Y, Yamato H, Murayama H, Takahashi
T, Ezawa I, Kurokawa K and Fukagawa M: Menatetrenone prevents
osteoblast dysfunction in unilateral sciatic neurectomized rats.
Jpn J Pharmacol. 90:88–93. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hori M, Uzawa T, Morita K, Noda T,
Takahashi H and Inoue J: Effect of human parathyroid hormone
(PTH(1–34)) on experimental osteopenia of rats induced by
ovariectomy. Bone Miner. 3:193–199. 1988.PubMed/NCBI
|
|
27
|
Fox J, Miller MA, Newman MK, Metcalfe AF,
Turner CH, Recker RR and Smith SY: Daily treatment of aged
ovariectomized rats with human parathyroid hormone (1–84) for 12
months reverses bone loss and enhances trabecular and cortical bone
strength. Calcif Tissue Int. 79:262–272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Iwaniec UT, Mosekilde L, Mitova-Caneva NG,
Thomsen JS and Wronski TJ: Sequential treatment with basic
fibroblast growth factor and PTH is more efficacious than treatment
with PTH alone for increasing vertebral bone mass and strength in
osteopenic ovariectomized rats. Endocrinology. 143:2515–2526. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hock JM, Gera I, Fonseca J and Raisz LG:
Human parathyroid hormone-(1–34) increases bone mass in
ovariectomized and orchidectomized rats. Endocrinology.
122:2899–2904. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alexander JM, Bab I, Fish S, et al: Human
parathyroid hormone 1–34 reverses bone loss in ovariectomized mice.
J Bone Miner Res. 16:1665–1673. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li M, Liang H, Shen Y and Wronski TJ:
Parathyroid hormone stimulates cancellous bone formation at
skeletal sites regardless of marrow composition in ovariectomized
rats. Bone. 24:95–100. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wronski TJ, Yen CF, Qi H and Dann LM:
Parathyroid hormone is more effective than estrogen or
bisphosphonates for restoration of lost bone mass in ovariectomized
rats. Endocrinology. 132:823–831. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Matsumoto T, Miyakawa T and Yamamoto D:
Effects of vitamin K on the morphometric and material properties of
bone in the tibiae of growing rats. Metabolism. 61:407–414. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Saito M and Marumo K: Collagen cross-links
as a determinant of bone quality: A possible explanation for bone
fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos
Int. 21:195–214. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Iwamoto J, Sato Y, Takeda T and Matsumoto
H: Bone quality and vitamin K2 in type 2 diabetes: Review of
preclinical and clinical studies. Nutr Rev. 69:162–167. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shiraishi A, Higashi S, Masaki T, Saito M,
Ito M, Ikeda S and Nakamura T: A comparison of alfacalcidol and
menatetrenone for the treatment of bone loss in an ovariectomized
rat model of osteoporosis. Calcif Tissue Int. 71:69–79. 2002.
View Article : Google Scholar : PubMed/NCBI
|
